Bryan Garnier - LYSOGENE (LYS.PA) LYSOGENE CORPORATE | EUR11 Reassuring news regarding LYS-SAF302

Report

Bryan Garnier

Jean-Jacques Le Fur

LYSOGENE CORPORATE | EUR11 Reassuring news regarding LYS-SAF302

º Good news regarding safety profile of LYS-SAF302
Phase III readout in Q2/Q3 2022

24/02/2022 1 EN

Underlying

LYSOGENE

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Jean-Jacques Le Fur

Other Reports on these Companies

Bryan Garnier

LYSOGENE: On the way for a positive phase III read out with LYS-SAF302? | CORPORATE | EUR11

LYSOGENE - CORPORATE | EUR11 On the way for a positive phase III read out with LYS-SAF302? Very encouraging preliminary results of AAVance phase III with LYS-SAF302 Safety signal are reassuring Final analysis is now mandatory to start discussion with health authorities

May 19, 2022 May 19, 2022 1 EN

Bryan Garnier

LYSOGENE: Lysogene continues to extend its pipeline | | EUR11

Lysogene announced that it exercised its option to in-license a program from Weizman institute in order to develop new gene therapy candidates targeting CNS diseases with GBA1 mutations. (Gaucher and Parkinson’s diseases).

April 13, 2022 April 13, 2022 1 EN

Carbios and Hündgen sign a MoU for feedstock supply

This morning, Carbios announced the signing of a non-binding Memorandum of Understanding with Hündgen, a waste management expect in logistics, sorting and recycling services. The MoU concerns the supply of 15kt/year of post-consumer PET waste to be recycled in the company's first commercial plant f

19h / 50m 19h / 50m 1 EN

Paul Charpentier

Paul Charpentier

Worldline - not as weak as expected, but too early to jump in

Worldline reported 2.5% organic growth in Q1 2024, weak in absolute terms but better than anticipated by the market and us. We wait for a clear uptick in momentum and the confirmation of an improved profitability to turn positive on the stock; which is arguably far from expensive at 5.1x EV/NTM EBI

20h / 8m 20h / 8m 1 EN

Cedric Rossi

Cedric Rossi

adidas: The best sunny terrace in sporting goods currently...

During the conference call, management tried to maintain a subtle equilibrium between presenting stronger-than-expected Q1 results and tempering somewhat analysts' optimism for FY24, as evidenced by a CSS estimate (EUR1.02bn) already standing well above ADS' revised guidance of "around EUR700m". We

20h / 26m 20h / 26m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

LYSOGENE CORPORATE | EUR11 Reassuring news regarding LYS-SAF302

LYSOGENE: On the way for a positive phase III read out with LYS-SAF302? | CORPORATE | EUR11

LYSOGENE: Lysogene continues to extend its pipeline | | EUR11

Carbios and Hündgen sign a MoU for feedstock supply

Worldline - not as weak as expected, but too early to jump in

adidas: The best sunny terrace in sporting goods currently...

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe